Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?

Elie Rassy (1, 2, 3) , Fabrice Andre (4, 5, 1)

1 IGR - Institut Gustave Roussy
2 CESP - Centre de recherche en épidémiologie et santé des populations
3 U1018 (Équipe 2) - Oncostat
4 Université Paris-Saclay
5 U981 - Biomarqueurs prédictifs et nouvelles stratégies moléculaires en thérapeutique anticancéreuse

This editorial calls for a strategic shift in our approach to cancers of unknown primary (CUP), one that generates a comprehensive multidimensional portrait of cancer in patients with CUP, to model the biology at the individual level and identify the right therapeutic target accordingly. The framework of this approach is based on the integration of basic biology, biotechnologies, data sciences, clinical research, and social sciences.

Domains: Cancer; Methods and statistics; Statistics [stat]; Other Statistics [stat.ML]; Methodology [stat.ME]

Elie Rassy, Fabrice Andre. Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?. Oncologist, 2023, 28 (10), pp.829-831. ⟨10.1093/oncolo/oyad248⟩. ⟨inserm-04564091⟩